Cyberknife fractionated radiotherapy for adrenal metastases: Preliminary report from a multispecialty Indian cancer care center

Trinanjan Basu, Tejinder Kataria, Ashu Abhishek, Deepak Gupta, Shikha Goyal, Shyam S Bisht, Karthick K Payaliappan, Vikraman Subhramani

Abstract


Purpose: Metastasis to adrenal gland from lung, breast, and kidney malignancies are quite common. Historically radiotherapy was intended for pain palliation. Recent studies with stereotactic body radiotherapy (SBRT) including Cyberknife robotic radiosurgery aiming at disease control brings about encouraging results. Here we represent the early clinical experience with Cyberknife stereotactic system from an Indian cancer care center. The main purpose of this retrospective review is to serve as a stepping stone for future prospective studies with non- invasive yet effective technique compared to surgery.

Methods: We retrospectively reviewed four cases of adrenal metastases (three: lung and one: renal cell carcinoma) treated with Cyberknife SBRT. X sight spine tracking was employed for planning and treatment delivery. Patients were evaluated for local response clinically as well as with PETCT based response criteria.

Results: With a median gross tumor volume of 20.5 cc and median dose per fraction of 10 Gy, two patients had complete response (CR) and two had partial response (PR) when assessed 8-12 weeks post treatment as per RECIST. There was no RTOG grade 2 or more acute adverse events and organs at risk dosage were acceptable. Till last follow up all the patients were locally controlled and alive.

Conclusion: Cyberknife SBRT with its unique advantages like non- invasive, short duration outpatient treatment technique culminating in similar local control rates in comparison to surgery is an attractive option. World literature of linear accelerator based SBRT and our data with Cyberknife SBRT with small sample size and early follow up are similar in terms of local control in adrenal metastases. Future prospective data would reveal more information on the management of adrenal metastases.


Keywords


Cyberknife; Adrenal Metastases; Local Control; PETCT Response; X Sight Spine Tracking

Full Text:

PDF

References


Lam KY, Lo CY. Metastatic tumours of the adrenal glands: A 30-year experience in a teaching hospital. Clin Endocrinol (Oxf) 2002; 56:95-101.

Wansaicheong G, Goh J. Adrenal metastases; Accessed July 22,103. Emedicine.com. Available from: http://www.emedicine.com/radio/TOPIC17.HTM

Kung AW, Pun KK, Lam K, et al. Addisonian crisis as presenting feature in malignancies. Cancer 1990; 65:177-9.

Soffen EM, Solin LJ, Rubenstein JH, Hanks GE. Palliative radiotherapy for symptomatic adrenal metastases. Cancer 1990; 65:1318-20.

Short S, Chaturvedi A, Leslie MD. Palliation of symptomatic adrenal gland metastases by radiotherapy. Clin Oncol (R Coll Radiol) 1996; 8:387-9.

Soejima T, Hirota S, Hishikawa Y, et al. Radiation therapy for adrenal metastases. Nippon Igaku Hoshasen Gakkai Zasshi 1997; 57:801-4.

Miyaji N, Miki T, Itoh Y, et al. Radiotherapy for adrenal gland metastasis from lung cancer: report of three cases. Radiat Med 1999; 17:71-5.

Oshiro Y, Takeda Y, Hirano S, et al. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 2011; 34:249-53.

Lim CM, Clump DA, Heron DE, Ferris RL. Stereotactic Body Radiotherapy (SBRT) for primary and recurrent head and neck tumors. Oral Oncol 2013; 49:40-6.

Yuan ZY, Meng MB, Liu CL, et al. Stereotactic body radiation therapy using the CyberKnife(®) system for patients with liver metastases. Onco Targets Ther 2014; 7:915-23.

Bahig H, Campeau MP, Vu T, et al. Predictive parameters of CyberKnife fiducial-less (XSight Lung) applicability for treatment of early non-small cell lung cancer: a single-center experience. Int J Radiat Oncol Biol Phys 2013; 87:583-9.

Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.

Shang CY, Kasper ME, Kathriarachchi V, et al. Can an alternative backround-corrected [18F] fluorodeoxyglucose (FDG) standard uptake value (SUV) be used for monitoring tumor local control following lung cancer stereotactic body radiosurgery? Int J Cancer Ther Oncol 2014; 2:020317.

Chawla S, Chen Y, Katz AW, et al. Stereotactic body radiotherapy for treatment of adrenal metastases. Int J Radiat Oncol Biol Phys 2009; 75:71-5.

Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience. Int J Radiat Oncol Biol Phys 2012; 82:919-23.

Oshiro Y, Takeda Y, Hirano S, et al. Role of radiotherapy for local control of asymptomatic adrenal metastasis from lung cancer. Am J Clin Oncol 2011; 34:249-53.

Lam KY, Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol 2002; 56:95-101.

Gunjur A, Duong C, Ball D, Siva S. Surgical and ablative therapies for the management of adrenal 'oligometastases' - A systematic review. Cancer Treat Rev 2014; 40:838-46.

Soffen EM, Solin LJ, Rubenstein JH, Hanks GE. Palliative radiotherapy for symptomatic adrenal metastases. Cancer 1990; 65:1318-20.

Miyaji N, Miki T, Itoh Y, et al. Radiotherapy for adrenal gland metastasis from lung cancer: Report of three cases. Radiat Med 1999; 17:71-5.

Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol 2007; 2:S94–100.

Cho AR, Lim I, Na II, et al. Evaluation of Adrenal Masses in Lung Cancer Patients Using F-18 FDG PET/CT. Nucl Med Mol Imaging 2011; 45:52-8.

Xu B, Gao J, Cui L, et al. Characterization of adrenal metastatic cancer using FDG PET/CT. Neoplasma 2012; 59:92-9.




DOI: http://dx.doi.org/10.14319/ijcto.0301.2

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

------------------------------------------------------------

International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.

------------------------------------------------------------

Number of visits since October, 2013
AmazingCounters.com